Alkermes (NASDAQ:ALKS) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Alkermes (NASDAQ:ALKS) in a research report sent to investors on Saturday morning. The brokerage issued a buy rating on the stock.

ALKS has been the subject of several other reports. UBS Group began coverage on Alkermes in a research note on Tuesday, October 17th. They set a neutral rating and a $31.00 price objective for the company. HC Wainwright reissued a neutral rating and set a $34.00 target price on shares of Alkermes in a research note on Thursday, July 27th. Mizuho cut their target price on Alkermes from $37.00 to $35.00 and set a buy rating for the company in a research note on Thursday, October 26th. Piper Sandler cut their target price on Alkermes from $37.00 to $35.00 and set an overweight rating for the company in a research note on Friday, October 27th. Finally, Evercore ISI raised Alkermes from an in-line rating to an outperform rating in a research note on Tuesday, October 24th. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Alkermes presently has an average rating of Moderate Buy and a consensus price target of $32.29.

Alkermes Stock Down 0.2 %

Alkermes stock opened at $24.18 on Friday. The stock has a 50-day simple moving average of $26.81 and a 200-day simple moving average of $28.92. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.53 and a current ratio of 2.91. The company has a market capitalization of $4.04 billion, a P/E ratio of 19.50 and a beta of 0.62. Alkermes has a fifty-two week low of $22.01 and a fifty-two week high of $33.71.

Alkermes (NASDAQ:ALKS) last posted its quarterly earnings data on Wednesday, October 25th. The company reported $0.50 EPS for the quarter, beating the consensus estimate of $0.31 by $0.19. The firm had revenue of $380.94 million during the quarter, compared to the consensus estimate of $366.18 million. Alkermes had a return on equity of 11.41% and a net margin of 13.50%. Equities research analysts expect that Alkermes will post 1.11 earnings per share for the current year.

Institutional Investors Weigh In On Alkermes

Institutional investors and hedge funds have recently modified their holdings of the company. Signaturefd LLC grew its holdings in shares of Alkermes by 121.2% in the 2nd quarter. Signaturefd LLC now owns 854 shares of the company’s stock worth $27,000 after acquiring an additional 468 shares during the period. Altshuler Shaham Ltd acquired a new stake in Alkermes during the 2nd quarter valued at $28,000. TCI Wealth Advisors Inc. grew its holdings in Alkermes by 105.4% during the 1st quarter. TCI Wealth Advisors Inc. now owns 908 shares of the company’s stock valued at $26,000 after buying an additional 466 shares during the last quarter. Neo Ivy Capital Management acquired a new stake in Alkermes during the 2nd quarter valued at $27,000. Finally, Emerald Advisers LLC acquired a new stake in Alkermes during the 3rd quarter valued at $27,000. Institutional investors and hedge funds own 95.21% of the company’s stock.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in the fields of neuroscience and oncology in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of product candidates in development for neurological disorders and cancer.